Recurrence of primary sclerosing cholangitis after living donor liver transplantation

Liver International

Volumn 27, Issue 1, 2007, Pages 86-94

  Tamura, Sumihito ^a   Sugawara, Yasuhiko ^a   Kaneko, Junichi ^a   Matsui, Yuichi ^a   Togashi, Junichi ^a   Makuuchi, Masatoshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Human leukocyte antigen; Living related donor; Primary sclerosing cholangitis

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; HLA B8 ANTIGEN; HLA DR3 ANTIGEN; MESALAZINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS; URSODEOXYCHOLIC ACID;

ACUTE GRAFT REJECTION; ADULT; ARTERY THROMBOSIS; ARTICLE; BILOMA; CAUCASIAN; CHOLANGIOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; ENDOSCOPIC SCLEROTHERAPY; ESOPHAGUS SURGERY; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; GENETIC SUSCEPTIBILITY; GRAFT SURVIVAL; HAPLOTYPE; HERPES ZOSTER; HUMAN; LIVER TRANSPLANTATION; LIVING DONOR; MALE; OVERALL SURVIVAL; PRIMARY SCLEROSING CHOLANGITIS; RECURRENT DISEASE; SPLENECTOMY; STOMACH PERFORATION; SURVIVAL RATE;

ADULT; CHOLANGITIS, SCLEROSING; FEMALE; GRAFT SURVIVAL; HUMANS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; RECURRENCE;

EID: 33846439809     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01395.x     Document Type: Article

References (59)

1. Chapman RW, Arborgh BA, Rhodes JM, et al. Primary sclerosing cholangitis: A review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21: 870-7.
2. Wiesner RH, Porayko MK, LaRusso NF, Ludwig J. Primary sclerosing cholangitis. In: Schiff L, Schiff ER, eds. Disease of the Liver, Vol. 1, 7th edn. Philadelphia: Lippincott, 1993; 411-26.
3. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332: 924-33.
4. Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis. Hepatology 1989; 10: 430-6.
5. Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology 1999; 30: 325-32.
6. Broome U, Olsson R, Loof L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610-5.
7. Narumi S, Roberts JP, Emond JC, Lake J, Asher NL. Liver transplantation for sclerosing cholangitis. Hepatology 1995; 22: 451-7.
8. Goss JA, Shackleton CR, Farmer DG, et al. Orthotopic liver transplantation for primary sclerosing cholangitis: A 12-year single center experience. Ann Surg 1997; 225: 472-83.
9. Graziadei IW, Wiesner RH, Marotta PJ, et al. Long term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999; 30: 1121-7.
10. Bjoro K, Schrumpf E. Liver transplantation for primary sclerosing cholangitis. J Hepatol 2004; 40: 570-7.
11. Boberg KM, Lundin KE, Schrumpf E. Etiology and pathogenesis in primary sclerosing cholangitis. Scand J Gastroenterol 1994; 204(Suppl.): 47-58.
12. Ponsioen CI, Tytgat GN. Primary sclerosing cholangitis: A clinical review. Am J Gastroenterol 1998; 93: 515-23.
13. Harrison RF, Davies MH, Neuberger JM, Hubscher SG. Fibrous and obliterative cholangitis in liver allografts: Evidence of recurrent primary sclerosing cholangitis. Hepatology 1994; 20: 356-61.
14. Sheng R, Campbell WL, Zajko AB, Baron RL. Cholangiographic features of biliary strictures after liver transplantation for primary sclerosing cholangitis: Evidence of recurrent disease. AJR 1996; 166: 1109-13.
15. Graziadei IW, Wiesner RH, Batts KP, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999; 29: 1050-6.
16. Kugelmas M, Spiegelman P, Osgood MJ, et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transplant 2003; 9: 727-32.
17. Hasegawa K, Sugawara Y, Imamura H, Ikeda M, Kokudo N, Makuuchi M. Living donor liver transplantation for primary biliary cirrhosis: Retrospective analysis of 50 patients in a single center. Transplant Int 2005; 18: 794-9.
18. Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000; 75: 688-94.
19. Sugawara Y, Mizuta K, Kawarasaki H, Takayama T, Imamura H, Makuuchi M. Risk factors for acute rejection in pediatric living related liver transplantation: The impact of HLA matching. Liver Transplant 2001; 7: 769-73.
20. Kokudo N, Sugawara Y, Imamura H, Sano K, Makuuchi M. Tailoring the type of donor hepatectomy for adult living donor liver transplantation. Am J Transplant 2005; 5: 1694-703.
21. Sugawara Y, Makuuchi M. Advances in adult living donor liver transplantation: A review based on reports from the 10th anniversary of the adult-to-adult living donor liver transplantation meeting in Tokyo. Liver Transplant 2004; 10: 715-20.
22. Urata K, Kawasaki S, Matsunami H, et al. Calculation of child and adult standard liver volume for liver transplantation. Hepatology 1995; 21: 1317-21.
23. Sugawara Y, Makuuchi M, Kaneko J, Ohkubo T, Imamura H, Kawarasaki H. Correlation between optimal tacrolimus doses and the graft weight in living donor liver transplantation. Clin Transplant 2002; 16: 102-6.
24. Kaneko J, Sugawara Y, Akamatsu N, et al. Prediction of hepatic artery thrombosis by protocol Doppler ultrasonography in pediatric living donor liver transplantation. Abdom Imaging 2004; 29: 603-5.
25. Kita Y, Lake JR, Ferrell LD, et al. Possible recurrence of primary sclerosing cholangitis following living-related liver transplantation: report of a case. Transplant Proc 1998; 30: 3321-3.
26. Wachs ME, Bak TE, Karrer FM, et al. Adult living donor liver transplantation using a right hepatic lobe. Transplantation 1998; 66: 1313-6.
27. Kaibori M, Uemoto S, Fujita S, et al. Native hepatectomy after auxiliary partial orthotopic liver transplantation. Transplant Int 1999; 12: 383-6.
28. Ikegami T, Nishizaki T, Yanaga K, et al. Living-related auxiliary partial orthotopic liver transplantation for primary sclerosing chonangitis-subsequent removal of the native liver. Hepatogastroenterol 1999; 46: 2951-4.
29. Nakamura M, Fuchinoue S, Nakajima I, et al. Three cases of sequential liver-kidney transplantation from living-related donors. Nephrol Dial Transplant 2001; 16: 166-8.
30. Varotti G, Gondolesi GE, Roayaie S, et al. Combined adult-to-adult living donor right lobe liver transplantation and pancreatoduodenectomy for distal bile duct adenocarcinoma in a patient with primary sclerosing cholangitis. J Am Coll Surg 2003; 197: 765-9.
31. Akyildiz M, Karasu Z, Cagirgan S, Kilic M, Tokat Y. Rituximab therapy for life-threatening immune hemolytic anemia in a liver tranplant recipient: A case report. Transplant Proc 2004; 36: 1492-3.
32. Oya H, Sato Y, Yamamoto S, Takeishi T, Kobayashi T, Hatakeyama K. Living related donor liver transplantation for primary sclerosing cholangitis with hepatocellular carcinoma and Crohn's disease: A case report. Transplant Proc 2004; 36: 2297-8.
33. Jabbour N, Gagandeep S, Mateo R, et al. Live donor liver transplantation: Staging hepatectomy in a Jehovah's Witness recipient. J Hepatobiliary Pancreat Surg 2004; 11: 211-4.
34. Heimbach JK, Menon KV, Ishitani MB, et al. Living donor liver transplantation using a right lobe graft in an adult with situs inversus. Liver Transplant 2005; 11: 111-3.
35. Bjoro K, Friman S, Hockerstedt K, et al. Liver transplantation in the Nordic countries, 1982-1998: Changes of indications and improving results. Scand J Gastroenterol 1999; 34: 714-22.
36. http://jlts.umin.ac.jp/annual/Registry(2004).pdf.
37. Moon DB, Lee SG. Adult-to-adult living donor liver transplantation at the Asan Medical Center. Yonsei Med J 2004; 45: 1162-8.
38. Soejima Y, Harada N, Shimada M, et al. Perioperative management and complications in donors related to living-donor liver transplantation. Surgery 2002; 131 (1 Suppl.): S195-9.
39. Solano E, Khakhar A, Bloch M, et al. Liver transplantation for primary sclerosing cholangitis. Transplant Proc 2003; 35: 2431-4.
40. Hayashi PH, Forman L, Steinberg T, et al. Model for end-stage liver disease score does not predict patient or graft survival in living donor liver transplant recipients. Liver Transplant 2003; 9: 737-40.
41. Maheshwari A, Yoo HY, Thuluvath PJ. Long-term outcome of liver transplantation in patients with PSC: A comparative analysis with PBC. Am J Gastroenterol 2004; 99: 538-42.
42. Harrison RF, Davies MH, Neuberger JM, Hubscher SG. Fibrous and obliterative cholangitis in liver allografts: Evidence of recurrent primary sclerosing cholangitis? Hepatology 1994; 20: 356-61.
43. Jeyarajah DR, Netto GJ, Lee SP, et al. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation. Transplantation 1998; 66: 1300-6.
44. Kubota T, Thomson A, Clouston AD, et al. Clinicopathologic findings of recurrent primary sclerosing cholangitis after orthotopic liver transplantation. J Hepatobiliary Pancreat Surg 1999; 6: 377-81.
45. Liden H, Norrby J, Friman S, Olausson M. Liver transplantation for primary sclerosing cholangitis - a single center experience. Transplant Int 2000; 13: S162-4.
46. Yusoff IF, House AK, De Boer WB, et al. Disease recurrence after liver transplantation in Western Australia. J Gastroenterol Hepatol 2002; 17: 203-7.
47. Vera A, Moledina S, Gunson B, et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002; 360: 1943-4.
48. Brandsaeter B, Schrumpf E, Bentdal O, et al. Recurrent primary sclerosing cholangitis after liver transplantation: A magnetic resonance cholangiography study with analyses of predictive factors. Liver Transplant 2005; 11: 1361-9.
49. Schrumpf E, Fausa O, Forre O, Dobloug JH, Ritland S, Thorsby E. HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand J Gastroenterol 1982; 17: 187-91.
50. Chapman RW, Varghese Z, Gaul R, Patel G, Kokinon N, Sherlock S. Association of primary sclerosing cholangitis with HLA-B8. Gut 1983; 24: 38-41.
51. Donaldson PT, Farrant JM, Wilkinson ML, Hayllar K, Portmann BC, Williams R. Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology 1991; 13: 129-33.
52. Farrant JM, Doherty DG, Donaldson PT, et al. Amino acid substitutions at position 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology 1992; 16: 390-5.
53. Olerup O, Olsson R, Hultcrantz R, Broome U. HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 1995; 108: 870-8.
54. Spurkland A, Saarinen S, Boberg KM, et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 1999; 53: 459-69.
55. Boberg KM, Spurkland A, Rocca G, et al. The HLA-DR3, DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis. Scand J Gastroenterol 2001; 36: 886-90.
56. Hashimoto M, Kinoshita T, Yamasaki M, et al. Gene frequencies and haplotypic associations within the HLA region in 916 unrelated Japanese individuals. Tissue Antigens 1994; 44: 166-73.
57. Tokunaga K, Ishikawa Y, Ogawa A, et al. Sequence-based association analysis of HLA class I and II alleles in Japanese supports conservation of common haplotypes. Immunogenetics 1997; 46: 199-205.
58. Saito S, Ota S, Yamada E, Inoko H, Ota M. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens 2000; 56: 522-9.
59. Itoh Y, Mizuki N, Shimada T, et al. High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population. Immunogenetics 2005; 57: 717-29.